Where Will Sorrento Therapeutics Be in 1 Year?
Last year, Sorrento Therapeutics (NASDAQ: SRNE) became one of the hottest coronavirus stocks. It's made an impressive gain of 135% since last January. However, many investors who joined the hype were quickly disappointed, as the stock fell nearly 50% from all-time highs in August.
The enormous volatility behind Sorrento stock is not without reason. It was among the first in the biotech sector to begin searching for ways to treat COVID-19. After the development of its coronavirus tests and therapeutics began to stall, shareholders started ditching the company in favor of its competitors.
Is Sorrento bound for a turnaround this year, or is the wait for results set to stretch even longer?
Source Fool.com
